Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VIR
SELLVir Biotechnology, Inc. · Healthcare · United States · $1.5B · Avg Vol: $19M/d
COMPANY DESCRIPTION
Vir Biotechnology, Inc. is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to develop novel solutions for serious infectious diseases. Its competitive moat lies in its proprietary technology platforms, including antibody engineering, T cell therapy, and in vivo gene editing, aimed at generating best-in-class therapies. Vir is a specialized biopharmaceutical firm, positioned at the forefront of infectious disease research and development.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 1.6B | 39.5M | 63.7M | 66.5M | -65.2% | 65.5M | 249.4M | 112.9M | 30.3% |
| EPS | 4.07 | 3.89 | -4.59 | -3.83 | -3.16 | -4.4% | -3.06 | — | — | — |
| Shares | — | 133.2M | 134.8M | 137.0M | 139.5M | +4.7% | 168.7M | — | — | — |
| Debt | — | 128.0M | 124.5M | 97.9M | 97.9M | -8.6% | 95.6M | — | — | — |
| Equity | — | 2.1B | 1.6B | 1.2B | 765.3M | -28.3% | — | — | — | — |
| Op CF | — | 1.7B | -778.8M | -446.4M | -391.8M | — | -446.1M | — | — | — |
| Inv CF | — | -1.2B | 164.6M | 499.4M | 310.4M | — | — | — | — | — |
| Fin CF | — | 34.8M | 7.5M | 4.4M | 3.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VIR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VIR | Vir Biotechnology, Inc.(you) | $1.5B | 32 | SELL |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | 29 | SELL |
| XNCR | Xencor, Inc. | $1.4B | 30 | SELL |
| SEPN | Septerna, Inc. | $1.5B | 35 | HOLD |
| BCAX | Bicara Therapeutics Inc. | $1.8B | 31 | SELL |
| JBIO | Jade Biosciences, Inc. | $1.2B | 33 | SELL |
| DMRA | Damora Therapeutics, Inc. | $1.8B | 30 | SELL |
| RAPP | Rapport Therapeutics, Inc. | $1.9B | 32 | SELL |
| MGTX | MeiraGTx Holdings plc | $1.1B | 32 | SELL |
| SRPT | Sarepta Therapeutics, Inc. | $1.7B | 36 | HOLD |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%